Relugolix

(Orgovyx®)

Relugolix

Drug updated on 12/19/2023

Dosage FormTablet (oral: 120 mg)
Drug ClassGonadotropin-releasing hormone receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with advanced prostate cancer.

Product Monograph / Prescribing Information

Document TitleYearSource
Orgovyx (relugolix) Prescribing Information.2022Myovant Sciences, Inc., Brisbane, CA

Randomized Controlled Trials